Kymera Therapeutics
Develops oral protein degraders for immunology and partnered oncology programs.
$118.15
After-hours close+0.07 (+0.06%)
At close$118.08(−1.79%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$1.25 | — | — |
| Aug 2026 | −$0.71 | −$0.62 | +13.0% |
| Apr 2026 | −$0.89 | −$0.71 | +20.2% |
| Feb 2026 | −$0.78 | −$0.97 | −23.8% |
| Nov 2025 | −$0.71 | −$0.90 | −26.8% |
The latest year is open to everyone — the 24 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| Jun 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | −$1.25 | — | — | $3.8M | — | — |
| Aug 5, 2026 | −$0.71 | −$0.62 | +13.0% | $32.8M | $65.0M | +98.3% |
| Apr 30, 2026 | −$0.89 | −$0.71 | +20.2% | $8.3M | $34.4M | +315.7% |
| Feb 26, 2026 | −$0.78 | −$0.97 | −23.8% | $15.0M | $2.9M | −80.9% |
| Nov 4, 2025 | −$0.71 | −$0.90 | −26.8% | $14.5M | $2.8M | −80.9% |
The latest year is open to everyone — the 24 quarters behind it read with an account. Sign in | ||||||
| Aug 11, 2025 | ||||||
| May 9, 2025 | ||||||
| Feb 27, 2025 | ||||||
| Oct 31, 2024 | ||||||
| Aug 7, 2024 | ||||||
| May 2, 2024 | ||||||
| Feb 22, 2024 | ||||||
| Nov 2, 2023 | ||||||
| Aug 3, 2023 | ||||||
| May 4, 2023 | ||||||
| Feb 23, 2023 | ||||||
| Nov 3, 2022 | ||||||
| Aug 9, 2022 | ||||||
| May 3, 2022 | ||||||
| Feb 24, 2022 | ||||||
| Nov 10, 2021 | ||||||
| Aug 6, 2021 | ||||||
| May 6, 2021 | ||||||
| Mar 11, 2021 | ||||||
| Nov 5, 2020 | ||||||
| Aug 21, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Dec 31, 2019 | ||||||
| Sep 30, 2019 | ||||||